James M. Frates - Mar 31, 2025 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Chief Financial Officer
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Stock symbol
AMLX
Transactions as of
Mar 31, 2025
Transactions value $
-$37,806
Form type
4
Date filed
4/2/2025, 05:22 PM
Previous filing
Mar 10, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Sale -$37.8K -10.9K -3.61% $3.47 291K Mar 31, 2025 Direct F1, F2
holding AMLX Common Stock 15.5K Mar 31, 2025 By Trust F3
holding AMLX Common Stock 11.1K Mar 31, 2025 By Trust F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.44 to $3.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
F4 Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.